Wuhan's promising anti-coronavirus drug trial gains WHO recognition

Wuhan's promising anti-coronavirus drug trial gains WHO recognition

The double-blind randomized controlled trial (RCT) of the antiviral drug Remdesivir, a possible treatment of the novel coronavirus, is underway in Wuhuan, and received recognition from the World Health Organization (WHO), during a press conference on Friday.

"Remdesivir is currently the strongest in antiviral activity in vitro, but there is lack of clinical trial evidence," said Zhao Jianping, expert of medical treatment unit of Hubei. Also the director of the Pulmonary and Critical Care Medicine at Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Zhao added that the efficacy and safety of the drug must be tested with scientific attitudes.